Search research articles
Contact Us
Filters
Showing results (11-20 of 74) with videos related to
Page
of 8
Sort By:
Diabetes & Metabolism
|
January 20, 2023
Incidence of new-onset type 1 diabetes during Covid-19 pandemic: A French nationwide population-based study
Anne-Sophie Mariet, Jean-Michel Petit, Eric Benzenine, et al.
Annales D'Endocrinologie
|
August 27, 2018
Expert opinion on the metabolic complications of mTOR inhibitors
Benjamin Bouillet, Perrine Buffier, Sarra Smati, et al.
Diabetes & Metabolism
|
March 4, 2022
Healing of diabetic foot ulcers is independently associated with the use of angiotensin receptor blockers but not with those of diuretics and angiotensin conversion enzyme inhibitors
Marion Lapray, Jean-Michel Petit, Coralie Fourmont, et al.
Clinical Pharmacology : Advances and Applications
|
February 12, 2021
Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
Alexia Rouland, Benjamin Bouillet, Pauline Legris, et al.
Acta Diabetologica
|
April 14, 2019
CETP activity is not associated with carotid intima-media thickness in patients with poorly controlled type 2 diabetes
Benjamin Bouillet, T Gautier, B Terriat, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
April 2, 2021
Impact of the COVID-19 Epidemic on hospitalization for diabetic foot ulcers during lockdown: A French nationwide population-based study
Anne-Sophie Mariet, Eric Benzenine, Benjamin Bouillet, et al.
Diabetes & Metabolism
|
September 22, 2021
Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Bruno Vergès, Jonathan Hassid, Alexia Rouland, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 20, 2014
No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones
Laurence Perségol, Laurence Duvillard, Serge Monier, et al.
Atherosclerosis
|
July 6, 2015
Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration
Damien Denimal, Jean-Paul Pais de Barros, Jean-Michel Petit, et al.
Metabolites
|
September 27, 2024
The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes
Alexia Rouland, Thomas Gautier, Damien Denimal, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 74) with videos related to
Sort By:
Page
of 8
Diabetes & Metabolism
|
January 20, 2023
Incidence of new-onset type 1 diabetes during Covid-19 pandemic: A French nationwide population-based study
Anne-Sophie Mariet, Jean-Michel Petit, Eric Benzenine, et al.
Annales D'Endocrinologie
|
August 27, 2018
Expert opinion on the metabolic complications of mTOR inhibitors
Benjamin Bouillet, Perrine Buffier, Sarra Smati, et al.
Diabetes & Metabolism
|
March 4, 2022
Healing of diabetic foot ulcers is independently associated with the use of angiotensin receptor blockers but not with those of diuretics and angiotensin conversion enzyme inhibitors
Marion Lapray, Jean-Michel Petit, Coralie Fourmont, et al.
Clinical Pharmacology : Advances and Applications
|
February 12, 2021
Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
Alexia Rouland, Benjamin Bouillet, Pauline Legris, et al.
Acta Diabetologica
|
April 14, 2019
CETP activity is not associated with carotid intima-media thickness in patients with poorly controlled type 2 diabetes
Benjamin Bouillet, T Gautier, B Terriat, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
April 2, 2021
Impact of the COVID-19 Epidemic on hospitalization for diabetic foot ulcers during lockdown: A French nationwide population-based study
Anne-Sophie Mariet, Eric Benzenine, Benjamin Bouillet, et al.
Diabetes & Metabolism
|
September 22, 2021
Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Bruno Vergès, Jonathan Hassid, Alexia Rouland, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 20, 2014
No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones
Laurence Perségol, Laurence Duvillard, Serge Monier, et al.
Atherosclerosis
|
July 6, 2015
Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration
Damien Denimal, Jean-Paul Pais de Barros, Jean-Michel Petit, et al.
Metabolites
|
September 27, 2024
The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes
Alexia Rouland, Thomas Gautier, Damien Denimal, et al.
Page
of 8